Russian government to refrain from state regulation of prices for cheap drugs
Prices for cheap drugs from the list of vital medicines may significantly increase in Russia this year due to a recent decision by the Russian government to refrain from further state regulation of prices for drugs from this segment.
That means that the government will allow pharmaceutical companies to set their own prices for such vital and cheap drugs as aspirin, ibuprofen, glycine, water for injection, etc, reports The Pharma Letter’s local correspondent.
The decision has already been confirmed by Russia’s first deputy Prime Minister Arkady Dvorkovich, according to whom it will affect drugs priced up to 50 roubles ($0.79). Mr Dvorkovich also said that, in order to prevent the increase of prices for these drugs, the government plans to provide subsidies for their producers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze